SCHEDULE: FMR LLC Discloses 5.6% Stake in Celldex Therapeutics

FMR LLC, through its affiliates, has reported beneficial ownership of 5.6% of Celldex Therapeutics Inc.'s common stock as of March 31, 2026.

Summary

• FMR LLC and Abigail P. Johnson, through various subsidiaries and affiliates, have filed a Schedule 13G indicating beneficial ownership of 3,749,048 shares of Celldex Therapeutics Inc. common stock.
• This represents 5.6% of the total outstanding common stock as of the event date, March 31, 2026.
• FMR LLC is classified as a holding company, while Fidelity Institutional Asset Management Trust Company and Fidelity Management & Research Company LLC are classified as banks and investment advisers, respectively.
• Strategic Advisers LLC is also identified as an investment adviser.
• Abigail P. Johnson is a Director, Chairman, and CEO of FMR LLC, and members of the Johnson family are predominant owners of FMR LLC's voting shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It's a standard disclosure of beneficial ownership by a major investment firm and does not provide new operational or financial information about the company itself.

Positives

• FMR LLC's significant stake suggests confidence in Celldex Therapeutics' long-term prospects.
• The filing indicates that the securities were acquired and are held in the ordinary course of business, not for the purpose of influencing control.

Negatives

• No specific financial performance data or operational updates are provided in this filing, as it is a Schedule 13G disclosure of beneficial ownership.

Risks

• The filing does not explicitly detail risks related to Celldex Therapeutics' business operations. However, as a Schedule 13G, it pertains to ownership and not operational risks of the issuer.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding Celldex Therapeutics' future performance.

Management Comments

• "This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the 'FMR Reporters')."
• "The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares."
• "Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC."

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for large institutional investors like FMR LLC (Fidelity) when their ownership stake in a public company crosses a reporting threshold. This filing indicates FMR's continued investment interest in the biotechnology sector, specifically in companies like Celldex Therapeutics.

Corporate Governance

Stakeholder Impact

• Shareholders: The filing confirms a significant institutional investor's stake, which can be viewed positively by other shareholders as a sign of confidence, but it does not directly impact current operations or immediate share price without further context.

Next Steps

• FMR LLC will continue to hold and potentially adjust its beneficial ownership of Celldex Therapeutics' common stock.
• Future filings will be made if ownership levels change significantly.

Key Dates

Keywords

Celldex Therapeutics, FMR LLC, Schedule 13G, Beneficial Ownership, Common Stock, Investment, Fidelity, Abigail P. Johnson, SEC Filing